looks like 1/3 of all the volume recently has been short sales. The positive here is that IF management has anything different to say from the usual name dropping, and lofty ambitions. [Meaning they announce some real positive fundamental changes. Not that they MAY POSSIBLY make $13MM from the Clinical Data, or that they MAY start selling the MMR Pro product with the new Kodak scanners, etc. I mean real positives, such as they signed a big client that will provide $x revs over x years, or they killed their crummy equity deal, or they are going to get some real revenue today from Celgene vs. some unstated, BS figure....]
IF they can deliver something of substance, then maybe the shorts will help us out by covering...
